Biologics

America’s insulin crisis just met its match. Biocon Biologics is mounting an aggressive expansion into the United States diabetes market, targeting millions of Americans struggling with soaring insulin costs. The fully integrated global biosimilars company, a subsidiary of Biocon Ltd., aims to provide high-quality, affordable insulin alternatives to approximately 38.4 million Americans living with diabetes—roughly

The biopharmaceutical industry’s most explosive growth story isn’t happening inside pharmaceutical giants’ research labs. It’s unfolding within specialized contract manufacturing organizations producing tomorrow’s life-saving therapies. The biologics contract manufacturing market will more than double from approximately $35.9 billion in 2025 to roughly $71.8 billion by 2032, reflecting compound annual growth exceeding 10%. This isn’t incremental

India’s healthcare boom has triggered an environmental emergency that most citizens never see. Every day, over 700 tonnes of potentially lethal waste emerge from hospitals nationwide. Syringes, blood-soaked dressings, pharmaceutical residues, and pathological materials pile up relentlessly. Mishandled, they become biological time bombs threatening communities and ecosystems alike. Yet within this crisis lies a burgeoning

Americans with diabetes face a brutal choice: pay exorbitant insulin prices or ration life-saving medication and risk severe health complications. This isn’t hyperbole—patients regularly skip doses, stretch supplies dangerously thin, or simply go without because insulin costs have spiraled beyond affordability for millions. Biocon Biologics, a global biosimilars leader, has extended its partnership with US-based

Most cancer treatments attack tumours directly with chemicals or radiation—blunt instruments causing collateral damage throughout the body. Theriva Biologics takes a fundamentally different approach: engineering viruses that selectively invade cancer cells, replicate inside them, and trigger immune responses while breaking down the protective barriers tumours build around themselves. This innovative strategy targets some of medicine’s

India manufactures the chemical compounds that keep millions alive globally, yet most people never realize these active pharmaceutical ingredients come from Indian factories. APIs—the actual therapeutic substances in medications—represent the foundation of every pill, injection, and treatment that global healthcare systems depend upon daily. India’s API market reached approximately $13 billion in 2023, producing over

Foreign investors grab headlines when they pump billions into Indian markets or trigger panic by pulling capital out. Yet India’s pharmaceutical industry increasingly depends on quieter, steadier hands—domestic institutional investors who don’t flee at the first sign of global turbulence. These homegrown investment powerhouses—mutual funds, insurance companies, pension funds, and banks—have fundamentally reshaped who finances

India’s biologics manufacturers just discovered something remarkable: going green actually saves money while winning international contracts simultaneously. Companies like Biocon, Sun Pharma, and Dr. Reddy’s aren’t embracing sustainable biomanufacturing because of environmental activism—they’re doing it because European and North American buyers now demand demonstrable green credentials for procurement contracts. India exported over $7 billion worth

India’s pharmaceutical industry has just placed a massive bet on artificial intelligence, and there’s no turning back now. Companies like Biocon, Dr. Reddy’s, and Cipla aren’t just experimenting with AI anymore—they’re integrating machine learning algorithms directly into drug discovery pipelines, clinical trial designs, and manufacturing processes. This shift from experimental pilots to strategic platforms represents